Lataa...

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

In April 2010, the European Medicines Agency Committee for Medicinal Products for Human Use recommended approval of roflumilast, a selective phosphodiesterase 4 inhibitor, for the “maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV(1) postbronchodilator less than 50% pr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Giembycz, Mark A, Field, Stephen K
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2010
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2915539/
https://ncbi.nlm.nih.gov/pubmed/20689641
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!